SCHEMBL18280076

SCHEMBL18280076

CC(C)(C)OC(=O)N1CCC(Cc2ccc(F)c3cccnc23)CC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.48
DTYMK P23919 1/20 0.46
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
ALOX5AP P20292 1/20 0.45
FEN1 P39748 1/20 0.45
POLB P06746 1/20 0.44
FAAH O00519 1/20 0.44
FNTA P49354 1/20 0.44
FNTB P49356 1/20 0.44
EPHX2 P34913 1/20 0.43
DPP4 P27487 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18280071 0.89 GPR119 (0.47) GPR119DTYMKKDM4EPKMPOLB
SCHEMBL18280093 0.88 GPR119 (0.47) GPR119DTYMKKDM4EPKMALOX5AP
SCHEMBL18280173 0.85 KDM4E (0.56) GPR119KDM4EPKMDPP4MAPT
SCHEMBL16825245 0.84 GPR119 (0.51) GPR119DTYMKKDM4EPKMPOLB
SCHEMBL8601284 0.84 GPR119 (0.53) GPR119DTYMKKDM4EPKMALOX5AP
SCHEMBL19284628 0.83 GPR119 (0.50) GPR119DTYMKALOX5APFEN1POLB
SCHEMBL18280179 0.83 GPR119 (0.47) GPR119DTYMKKDM4EPKMALOX5AP
SCHEMBL2774377 0.82 GPR119 (0.52) GPR119POLBEPHX2
SCHEMBL18228507 0.80 GPR119 (0.53) GPR119DTYMKKDM4EPKMALOX5AP
SCHEMBL28191247 0.80 GPR119 (0.48) GPR119DTYMKKDM4EPKMALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9902712-B2 Nitrogenous heterocyclic derivatives and their application in drugs SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-02-27 US disclosed
EP-3083584-B1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF TISSUE FIBROSIS SUNSHINE LAKE PHARMA CO LTD (CN) 2018-02-21 EP disclosed
US-20160355501-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160355501-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS TNNC1, IAPP, TNNI3 GPR119 331/4885DTYMK 2890/4885KDM4E 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.